Paek, Kyungyeol
Kim, Go-woon
Ahn, So Yeong
Lim, Joon Hyuk
Jung, Dongkeum
Kim, Seokkyun
Lee, Jae Hee http://orcid.org/0000-0002-8355-1734
Funding for this research was provided by:
Samsung Bioepis Co., Ltd.
Article History
First Online: 23 September 2019
Compliance with Ethical Standards
:
: This work was funded by Samsung Bioepis Co., Ltd.
: Kyungyeol Paek, Go-woon Kim, So Yeong Ahn, Joon Hyuk Lim, Dongkeum Jung, Seokkyun Kim, and Jae Hee Lee are employees of Samsung Bioepis. All authors declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.
: The combination studies described herein were performed solely to observe the effect of the presence of pertuzumab on the main modes of action of biosimilar trastuzumab at an in vitro cell-based level. The views expressed in this article are those of the authors alone and are made in a scientific capacity only. It should not be inferred that the authors, or Samsung Bioepis, are making any legal or regulatory representations regarding trastuzumab or pertuzumab. Nothing in this article should be taken to promote, encourage, or endorse use of biosimilar trastuzumab outside the scope of any authorized therapeutic indications or inside the scope of any valid intellectual property rights.